| Lukan N, Ströbel P, Willer A, et al.
Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. [JOURNAL ARTICLE]
Oncology 2009 Nov 17; 77(5):293-299.
Abstract | Full Citation | | Mancl EE, Kolesar JM, Vermeulen LC
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. [JOURNAL ARTICLE]
Am J Health Syst Pharm 2009 Dec 1; 66(23):2105-2112.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ryuge S, Jiang SX, Wada M, et al.
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan. [JOURNAL ARTICLE]
Drug Des Devel Ther 2009.:213-217.
Abstract | Full Citation | Find Related Articles | | Yoshioka T, Kato S, Gamoh M, et al.
Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. [JOURNAL ARTICLE]
Br J Cancer 2009 Nov 17.
Abstract | Full Citation | Find Related Articles | | Reardon DA, Desjardins A, Vredenburgh JJ, et al.
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. [JOURNAL ARTICLE]
Br J Cancer 2009 Nov 17.
Abstract | Full Citation | | Yashiki C, Hirose T, Okuda K, et al.
[Chemotherapy-Induced Myelosuppression and Treatment Efficacy in Extensive-Stage Small Cell Lung Cancer.] [JOURNAL ARTICLE]
Gan To Kagaku Ryoho 2009 Nov; 36(11):1839-1843.
Abstract | Full Citation | Find Related Articles | | Parker RB, Laizure SC
The Effect of Ethanol on Oral Cocaine Pharmacokinetics Reveals an Unrecognized Class of Ethanol-Mediated Drug Interactions. [JOURNAL ARTICLE]
Drug Metab Dispos 2009 Nov 17.
Abstract | Full Citation | Find Related Articles | | Green RM, Cloughesy TF, Stupp R, et al.
Bevacizumab for recurrent ependymoma. [Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't]
Neurology 2009 Nov 17; 73(20):1677-80.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Ciardiello F, Tejpar S, Papamichael D
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer. [JOURNAL ARTICLE]
Target Oncol 2009 Nov 14.
Abstract | Full Citation | | Artac M, Bozcuk H, Pehlivan S, et al.
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens. [JOURNAL ARTICLE]
J Cancer Res Clin Oncol 2009 Nov 12.
Abstract | Full Citation |   |
|
| |
Advertise on this site.
|
